The CBX6 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This product features targeted disruption of the CBX6 gene, which encodes a chromodomain protein that specifically recognizes trimethylated histone H3 lysine 27 (H3K27me3). As a core component of the Polycomb repressive complex 1 (PRC1), CBX6 is essential for targeting the complex to designated genomic loci. The polyclonal nature of this pool preserves a heterogeneous array of editing events, providing a robust loss-of-function model free from clonal bias.
The A-549 host cell line originates from a 58-year-old male with lung adenocarcinoma and displays adherent epithelial morphology. It retains features of alveolar type II pneumocytes and carries a KRASG12S mutation, making it a widely employed model for non-small cell lung cancer (NSCLC) research. A-549 cells are routinely used to investigate tumor cell proliferation, migration, invasion, and drug sensitivity, offering a clinically relevant backdrop for epigenetic studies.
Mechanistically, CBX6 binds H3K27me3 deposited by PRC2 subunits including EZH2 and SUZ12, subsequently recruiting PRC1 partners RING1B and BMI1 to catalyze monoubiquitination of H2A at lysine 119 (H2AK119ub). This step induces chromatin compaction and long-term silencing of target genes such as the HOX clusters and CDKN2A (p16INK4a). CBX6 activity is modulated by upstream signals like retinoic acid and the ANRIL lncRNA, and it functionally intersects with Wnt and TGF-?? signaling networks. Through these interactions, CBX6 coordinates cell cycle progression, differentiation, and epigenetic plasticity.
In the A-549 adenocarcinoma setting, CBX6-mediated gene repression contributes to oncogenic transcriptional programs by silencing tumor suppressor loci and differentiation factors. Genetic disruption of CBX6 in this polyclonal pool relieves PRC1-dependent silencing, leading to derepression of these targets, which can attenuate proliferation and colony-forming capacity, induce apoptosis, and reduce migratory and invasive behavior. The model thus permits systematic dissection of polycomb-driven epigenetic dependencies in NSCLC, enabling examination of compensatory crosstalk among PRC1 paralogs and evaluation of CBX6 as a therapeutic vulnerability.
Researchers can apply this polyclonal knockout population in a broad range of assays: chromatin immunoprecipitation-qPCR for H3K27me3 and H2AK119ub; RT-qPCR and western blot for target genes and PRC components; proliferation, colony formation, and transwell migration/invasion assays; annexin V apoptosis assays; immunofluorescence for PRC1 localization; and transcriptome-wide RNA-seq. It also serves as a critical tool for validating PRC1-targeted therapeutics and CRISPR off-target screening. For ordering and technical inquiries, contact Ascent Research.
